Evenity Gets CHMP Nod On Second Pass
UCB/Amgen Osteoporosis Drug Will Still Face Market Challenges
UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.
